Toxicité des antipaludéens dans le traitement du Sars-Cov-2 (notice n° 431951)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02460cam a2200385 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250120233824.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Mounir, Radia |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Toxicité des antipaludéens dans le traitement du Sars-Cov-2 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 75 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | To date, treatment options for severe COVID-19 remain limited and there are currently no effective drugs or vaccines for the treatment or prevention of SARS-Cov-2 that are specific for treating severely ill patients. Most potential drugs are being studied for their safety and efficacy against SARS-Cov-2, including antimalarials. Several countries are advocating the use of these antimalarials to treat SARS-Cov-2. Knowledge of the adverse effects of antimalarials in the treatment of SARS-Cov-2 (COVID-19) is the basis for better prevention and also for better management of these patients. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | À ce jour, les options thérapeutiques pour la Covid-19 sévère restent limitées et il n’existe actuellement aucun médicament ni vaccin efficace pour le traitement ou la prévention du Sars-Cov-2 spécifique pour traiter les patients gravement malades. La plupart des médicaments potentiels sont à l’étude pour leur innocuité et leur efficacité contre le Sars-Cov-2, parmi eux on trouve les antipaludéens. Plusieurs pays préconisent l’utilisation de ces antipaludéens pour traiter le Sars-Cov-2. La connaissance des effets indésirables des antipaludéens dans le traitement du Sars-Cov-2 (Covid-19) est la base d’une meilleure prévention et également d’une meilleure prise en charge de ces patients. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antipaludéens |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | effets indésirables |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | coronavirus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | toxicité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Covid-19 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Sars-Cov-2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | toxicity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | coronavirus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | SARS-Cov-2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | adverse effects |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antimalarials |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | COVID-19 |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Moutaouakkil, Youssef |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mamad, Hassan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ouggague, Kaoutar |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Iken, Maryem |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Naoui, Hafida |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lmimouni, Badreddine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Cahiers Santé Médecine Thérapeutique | 30 | 2 | 2021-03-01 | p. 91-96 | 2780-8858 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2021-2-page-91?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2021-2-page-91?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux